CRMP2 Sumoylation- a Biomarker for Chronic PainTechnology #ua17-019
Questions about this technology? Ask a Technology Manager
Title: CRMP2 SUMOylation - A Biomarker for Chronic Pain
Invention: This technology pertains to the implementation of CRMP2 SUMOylation as a novel objective biomarker to guide drug development and clinical practice for pain management.
Background: The current success rate of treating chronic pain is approximately 30%. Both treatment and research into chronic pain are greatly compromised by the fact that there is no objective biomarker for accurate diagnosis of chronic pain. As of now, pain diagnosis relies heavily on subjective assessment. SUMOylation of CRMP2 is associated to chronic pain and could be used as a measurable biomarker of pain.
- Development of an objective biomarker for chronic pain and neuropathic pain
- Biomarker for diagnosis, prediction of pain level, and assessment of treatment efficiency
- Potential to predict pain level and treatment efficiency
- CRMP2 SUMOylation regulates Nav1.7 expression, a validated target for chronic pain treatment
- Potential for use in stratifying patients that would respond to treatments targeting this pathway
- Potential for development of a companion diagnostic